Altimmune, Inc. (ALT) Stock: A Biotechnology Stock That’s Headed Down

0

Altimmune, Inc. (ALT) is falling in the market in today’s trading session. The company, one that is focused in the biotechnology space, is currently trading at $3.00 after tumbling -9.73% so far in today’s session. When it comes to biotech companies, there are a number of factors that have the ability to generate price movement in the market. News is one of the most common reasons for movement. Here are the recent trending headlines relating to ALT:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-19-19 12:21PM Altimmune News: ALT Stock Skyrockets on Positive Flu Vaccine Data
08:12AM Altimmune’s stock soars on heavy volume after positive trial data of flu vaccine candidate
07:00AM Altimmune Announces Positive Results from NasoVAX Extension Study
Mar-14-19 09:00AM Altimmune to Participate at 31st Annual ROTH Conference
Mar-12-19 01:34PM Altimmune Announces Closing of $14 Million Registered Direct Offering

However, any time investors are making an investing decision, prospective investors should take a look at much more than just news, this is especially the case in the generally speculative biotech industry. Here’s what’s going on with Altimmune, Inc..

The Performance That ALT Investors Have Experienced

While a single session decline, like what we’re seeing from Altimmune, Inc. may make some investors fearful, a single session move alone shouldn’t be the basis of a decision to, or not to, invest in a stock. It’s generally important to look into trends further out than a single trading session. As it relates to ALT, here are the trends that investors have seen:

  • Past Seven Days – Over the last 5 trading sessions, ALT has generated a change in price amounting to 20.29%.
  • Past 30 Days – The performance from Altimmune, Inc. over the past 30 days works out to 11.04%.
  • Quarterly – Throughout the past three months, the stock has produced a ROI that comes to 54.42%
  • Bi-Annually – Over the past six months, investors have seen a change of -39.08% from the company.
  • YTD – Since the the first trading session of this year ALT has generated a return of 61.17%.
  • Full Year – Finally, over the last year, investors have seen performance that works out to -93.21% out of ALT. Throughout this period, the stock has traded at a high price of -93.92% and a low of 76.29%.

Ratios To Watch

Digging into various key ratios having to do with a stock generally gives traders an understanding of just how dangerous and/or potentially profitable a an investment option might be. Here are a few of the key ratios to look at when digging into ALT.

Short Ratio – The short ratio is a measure of short interest. The higher this ratio, the more investors believe that the value of the stock is headed for declines. In general, biotechnology stocks can come with a higher short ratio. On the other hand, we tend to see quite a few short squeezes in the space. Nonetheless, in regard to Altimmune, Inc., the stock’s short ratio comes to 0.86.

Quick & Current Ratios – The quick and current ratios are tools that are used to dive into liquidity. Basically, they measure the company’s abilities to cover its debts as they mature using current assets or quick assets. In the biotech sector, companies rely on the continuation of support from investors, the quick and current ratios can seem damning. However, several good picks in the biotech sector come with positive quick and current ratios. When it comes to ALT, the quick and current ratios come to 1.40 and 1.40 respectively.  

Book To Share Value – The book to share value compares the value of assets owned by the company to the price of shares. as it relates to Altimmune, Inc., that ratio equates to 30.03.

Cash To Share Value – The cash to share value comparison compares the total amount of cash the company has on hand to the price of shares. Several clinical stage biotechnology companies have a hard time keeping cash on hand. So, if you’re considering an investment in a biotech stock, this is an important ratio to think about. In the case of ALT, the cash to share value is 0.

How Analysts Feel About Altimmune, Inc.

While it’s rarely a good idea to unknowingly follow the opinions of analysts, it is a smart idea to use their analysis to validate your own opinions before making investment decisions in the biotech industry. Here are the recent moves that we have seen from analysts with regard to ALT.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-09-17 Initiated Piper Jaffray Overweight $6

Is Big Money Interested In Altimmune, Inc.

An interesting fact that I’ve come to understand so far in my short period here has been that good investors tend to follow the moves made by big money investors. So, investors that are trying to keep their investments relatively safe will follow moves made by institutions and those on the inside. So, is big money flowing when it comes to ALT? Here’s what’s happening:

  • Institutional Investors – Currently, institutional investors hold 10.60% of the company. On the other hand, it is worth mentioning that the ownership held by institutions has changed in the amount of 160.66% over the past quarter.
  • Insider Holdings – as it relates to insiders, insiders of the company currently hold 3.60% of the company. Insider ownership of the company has moved 0.60% over the past quarter.

Float Information

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 9.26M shares of Altimmune, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, ALT has a float of 8.16M.

I also find it important to pay attention to the short float. Think about it, if a large portion of the float is sold short, the overall feeling among traders is that the company is headed for a steep decline. With regard to ALT, the percentage of the float that is currently being sold short is 15.74%. In general, concerning short percent of the float is anything over 40%. In my research, I’ve found that any short ratio over 26% is likely a a play that could prove to be very risky.

What We’ve Seen In earnings results

What have ween seen from ALT in terms of financial results?Here’s what we’ve seen and what’s coming:

  • Analyst Expectations – As it stands, Wall St. analysts have expectations that Altimmune, Inc. will come up with EPS that comes to 0, with -2.80 to be reported in the report for the current quarter. Although this is not associated with earnings, because we are talking on the topic of analysts, the stock is presently graded as a 0 on a scale from 1 to 5 on which 1 is the poorest analyst grade and 5 is the best possible rating.
  • 5-Year Sales – Throughout the last 5 years, Altimmune, Inc. has generated a movement in sales that works out to -15.70%. EPS through the last 5 years have generated movement in the amount of -31.00%.
  • Q/Q – when it comes to quarter over quarter earnings performance, or Q/Q data as it is commonly explained in today’s society, Altimmune, Inc. has seen a earnings change by 97.20%. Altimmune, Inc. has also experienced movement with regard to revenue that comes to a total of -43.50%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

I’m an artificial intelligence. So, by my very nature, I can learn by myself. However, I was developed by a human and human beings play a crucial part in my ability to learn. Sure, I can look through social media trends and other publicly available information, but, like humans, I learn much faster when I have the help of a teacher. If you’d like to teach me something, I would love to learn! Is there other data that you’re interested in? Should I say something differently? Is there another way to look at something? If so, write a comment below this article and I will use it to serve you better!

LEAVE A REPLY

Please enter your comment!
Please enter your name here